Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals.

Lockett S, Verma C, Brafman A, Gudla P, Nandy K, Mimaki Y, Fuchs PL, Jaja J, Reilly KM, Beutler J, Turbyville TJ.

Cytometry A. 2014 Jun;85(6):512-21. doi: 10.1002/cyto.a.22442. Epub 2014 Feb 11.

2.

Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.

Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

Phytochem Lett. 2014 Feb 1;7:42-45.

3.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013. Erratum in: PLoS One. 2014;9(6):e101827.

4.

Process and outcomes of patient-centered medical care with Alaska Native people at Southcentral Foundation.

Driscoll DL, Hiratsuka V, Johnston JM, Norman S, Reilly KM, Shaw J, Smith J, Szafran QN, Dillard D.

Ann Fam Med. 2013 May-Jun;11 Suppl 1:S41-9. doi: 10.1370/afm.1474.

5.

Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.

Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

J Nat Prod. 2013 Jan 25;76(1):59-63. doi: 10.1021/np300696g. Epub 2012 Dec 26.

6.

Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman KW, Reilly KM.

Neuro Oncol. 2012 Feb;14(2):160-74. doi: 10.1093/neuonc/nor206. Epub 2012 Jan 10.

7.

Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Amlin-Van Schaick J, Kim S, Broman KW, Reilly KM.

Mamm Genome. 2012 Apr;23(3-4):277-85. doi: 10.1007/s00335-011-9380-0. Epub 2011 Dec 8.

8.

Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.

Gürsel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC, Reilly KM.

Neuro Oncol. 2011 Jun;13(6):610-21. doi: 10.1093/neuonc/nor035.

9.

Back to the future: proceedings from the 2010 NF Conference.

Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG.

Am J Med Genet A. 2011 Feb;155A(2):307-21. doi: 10.1002/ajmg.a.33804. Epub 2010 Dec 22.

10.

Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.

Turbyville TJ, Gürsel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, Wiemer DF, Beutler JA, Reilly KM.

Mol Cancer Ther. 2010 May;9(5):1234-43. doi: 10.1158/1535-7163.MCT-09-0834. Epub 2010 May 4.

11.

Genetically engineered mouse models in cancer research.

Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.

Adv Cancer Res. 2010;106:113-64. doi: 10.1016/S0065-230X(10)06004-5. Review.

12.

Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency.

Pemov A, Park C, Reilly KM, Stewart DR.

BMC Genomics. 2010 Mar 22;11:194. doi: 10.1186/1471-2164-11-194.

13.

Neurofibromatosis and lessons for the war on cancer.

Reilly KM.

EMBO Mol Med. 2009 Jul;1(4):198-200. doi: 10.1002/emmm.200900029.

14.

Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner.

Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quiñones OA, Reilly KM.

Mamm Genome. 2009 Apr;20(4):214-23. doi: 10.1007/s00335-009-9179-4. Epub 2009 Apr 4.

15.
16.

Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk.

Reilly KM.

Brain Pathol. 2009 Jan;19(1):121-31. doi: 10.1111/j.1750-3639.2008.00236.x.

17.

It takes a (dysfunctional) village to raise a tumor.

Reilly KM, Van Dyke T.

Cell. 2008 Oct 31;135(3):408-10. doi: 10.1016/j.cell.2008.10.009.

18.

Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.

Hawes JJ, Nerva JD, Reilly KM.

J Biomol Screen. 2008 Sep;13(8):795-803. doi: 10.1177/1087057108321085. Epub 2008 Jul 29.

19.

Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop.

Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, Gutmann DH.

Cancer Res. 2008 Jul 15;68(14):5508-11. doi: 10.1158/0008-5472.CAN-08-0703. No abstract available.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk